Clinical Trial Update: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating FID-007 in combination with cetuximab for advanced head and neck squamous cell carcinoma is currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• FID-007

Snippet

Sponsor: Fulgent Pharma LLC. | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING